Bimekizumab (dual IL-17F and IL-17A inhibitor) phase 3 study for treatment of active ankylosing spondylitis demonstrated ASAS40 improvement at wk 14 (44% vs. 25%). #EULAR2022 @RheumNow #ABSTOP0019 https://t.co/eohvNFG3GS